focus -WSS

focus

author：entertainment 2025-09-06 04:50:46 - browse：39

empty test tubes in the hand. -- first opinion coverage from STAT — Adobe

The Food and Drug Administration on Friday announced its intention to start regulating tests developed in laboratories — closing the “Theranos loophole” that has allowed inaccurate tests to slip through the cracks.

Lawmakers came close last year to passing a bill that would have given the FDA this authority, but it was ultimately rejected by Republicans who sympathized with the labs in academic medical centers and hospitals that opposed the provision. FDA Commissioner Robert Califf said at the time that if the bill failed, the agency would take matters into its own hands.

The proposed rule fulfills that promise, adding lab diagnostics to the list of devices that fall under FDA enforcement — a move that patient groups and non-lab test makers support, and that laboratories are likely to dispute. When the FDA started regulating medical devices in 1976, lab-developed tests were simple and offered mostly to local patient populations. The agency generally allowed labs to use these tests without submitting proof of their efficacy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： How AI can help patients find reliable information about doctors

Wikipedia

WSS

How AI can help patients find reliable information about doctors

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Roche acquires Telavant from Roivant, adding experimental IBD treatment

STAT Readout: Friday, Oct. 20 biotech updates

People with substance use disorder deserve online privacy

Chamber of Commerce, DOJ clash in court over drug prices

explore

focus

focus

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

United colonoscopy coverage change 'may cost lives,' doctors say

Fed up with FDA, ALS advocates consider a take

State Dept. review finds Biden bears some blame for Afghanistan failures

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

United colonoscopy coverage change 'may cost lives,' doctors say

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Walensky prepares to leave CDC — and Congress — behind

Medicare to pay more for cardiac rehab in hospital outpatient clinics

leisure time

Is there really a nursing shortage in the U.S.?

FDA weighs limits of animal data in assessing artificial wombs

Questions loom on AstraZeneca cancer drug as safety concerns ebb

STAT Summit: Ending the crisis of Black deaths in the U.S.

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Information blocking fines are now fair game in health care

Wikipedia

Wikipedia

focus

hotspot